Dr Christian Toouli, CEO and Managing Director of FivepHusion, said, "The ethics approval of the Phase II DART protocol is an exciting milestone towards our goal of evaluating Deflexifol as a promising therapy for these patients."

Dr Chris Baldwin, CEO and Managing Director, said, “Receipt of ethics approval for our KappaMab Phase 2b clinical trial in combination with pomalidomide and dexamethasone is a significant milestone for HaemaLogiX."

Percheron Therapeutics has announced the successful completion of manufacturing for a new batch of HMBD-002 drug substance ahead of planned clinical trials.

Neurizon Therapeutics has executed a long-term supply agreement with Elanco Animal Health that gives the company access to scalable Good Manufacturing Practice supply of monepantel, the active pharmaceutical ingredient in its lead asset NUZ‑001.

Melbourne-based Dimerix has granted Everest Medicines exclusive rights to commercialise DMX 200 for all indications, including Focal Segmental Glomerulosclerosis, in China, South Korea, and parts of Southeast Asia.

Paradigm Biopharmaceuticals has announced the completion of enrolment in its pivotal Phase 3 trial of Zilosul injectable pentosan polysulfate sodium for knee osteoarthritis, a milestone that moves the company into the next phase of clinical and corporate catalysts.

Nyrada says its PROTECT MI Phase 2a study of Xolatryp remains on track for completion in calendar 2027 and is moving through the staged rollout typical of first-in-patient cardiovascular studies.

Entropy CEO Jason Carroll said, “The DSMB’s recommendation to progress to Cohort 2 without any protocol changes is an important milestone for the TRP-8803 program and provides independent validation of the favourable safety profile observed in Cohort 1.”

Memphasys has announced a 12-month exclusive national supply agreement with Monash IVF Group for the Felix automated sperm selection system.

The survey found that 82 per cent of biotech companies six years and older agreed they would experience a significant impact. 36 respondents (61 per cent) said the proposed changes to the Capital Gains Tax would negatively affect them.

Andy Wong, Head of Innovation and Technology (Life and Health Sciences) at InvestHK, recently returned to Hong Kong after attending the AusMedtech Conference in Perth.

Prescient Therapeutics has announced that Dr Rosalind Wilson will become its Chief Medical Officer, a move the clinical-stage oncology company says will strengthen its clinical and strategic capabilities as it advances multiple programs.

Australian cell therapy company Cartherics has announced that the Japanese Patent Office has issued a new patent for its off-the-shelf immune cell therapies.

CEO and Managing Director Dr David Foster said, “The expansion of our CRADA with USAMRIID and Geneva represents a major strategic milestone for Island and positions the Company to undertake the efficacy study prior to the pivotal study for Galidesivir.”

“We want to work with the Government to get these policy settings right and at speed so we can give Australia’s biotech, medtech and health tech companies the policy certainty they need to continue to thrive. We just need Government to meet us at the table,” said AusBiotech CEO Rebekah Cassidy.

Alterity Therapeutics has announced that the US Food and Drug Administration has agreed on the key design elements for a pivotal Phase 3 trial of ATH434 in Multiple System Atrophy following a successful End of Phase 2 meeting.

The company said the FDA correspondence represents a significant regulatory milestone because it completes the substantive review and moves the filing to the last administrative step before a decision.

LTR Pharma has taken a decisive step toward bringing its rapid-acting intranasal erectile dysfunction treatment ROXUS to the United States by signing a binding term sheet with Shed Holdings, a US direct-to-consumer telehealth platform.

Researchers at the Snow Centre for Immune Health have uncovered subtle but consistent differences in immune cell behaviour in people with coeliac disease, suggesting risk may arise from how the immune system functions long before symptoms appear.